[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"robotic-surgical-procedures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:robotic-surgical-procedures":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,67,91,116,146,168,193,216,240,270,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100640321","single-port-versus-conventional-laparoscopic-surgery-for-radical-proximal-gastric-cancer-a-randomized-controlled-trial-100640321",false,"NCT07586384","Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial","A Prospective, Single-center, Randomized Control Led Study of Laparoscopic Single-port Surgery System Versus Traditional Laparoscopic Surgery in Radical Proximal Gastric Cancer","Inclusion Criteria:\n\n* Age between 18 and 75 years inclusive.\n\nECOG performance status ≤ 2.\n\nHistologically confirmed proximal gastric cancer or Siewert type II adenocarcinoma of the esophagogastric junction.\n\nClinical stage cT1-T3, N0-N+, M0.\n\nTumor maximum diameter ≤ 4 cm and esophageal invasion ≤ 2 cm.\n\nCandidates for radical proximal gastrectomy (PG) with feasibility of R0 resection and functional anastomosis.\n\nAssessed by a Multidisciplinary Team (MDT) as suitable for PG rather than total gastrectomy, with no requirement for neoadjuvant therapy.\n\nRadiographic evidence of localized disease (no distant metastasis to liver, lung, or peritoneum via enhanced CT or MRI).\n\nASA physical status classification ≤ III.\n\nAdequate bone marrow, hepatic, renal, cardiac, and pulmonary function.\n\nAbility to understand and provide written informed consent.\n\nWillingness and ability to comply with the 12-month postoperative follow-up schedule.\n\nExclusion Criteria:\n\n* Clinical stage T4 or presence of distant metastasis.\n\nEsophageal invasion exceeding 2 cm.\n\nHistory of previous major gastric surgery (e.g., partial or total gastrectomy).\n\nOther malignant tumors within the last 5 years.\n\nSevere organic diseases that preclude safe anesthesia or surgery (e.g., severe heart failure, pulmonary fibrosis).\n\nRequirement for emergency surgery due to active gastric bleeding, perforation, or acute obstruction.\n\nPregnant or lactating women.\n\nSerious psychiatric disorders or cognitive impairment that interferes with study compliance.\n\nAny other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.","ALL","18 Years","80 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","To evaluate the safety and efficacy of SP1000 and conventional laparoscopy in radical gastrectomy for proximal gastric cancer.",[27,28],"Stomach Neoplasms","Robotic Surgical Procedures","RECRUITING","2026-05-08",{"date":32,"type":33},"2026-05-14","ACTUAL",{"date":35,"type":33},"2025-11-05",{"date":37,"type":21},"2027-09-30",{"name":39,"class":40},"First Affiliated Hospital of Wenzhou Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100626674","outcomes-of-pediatric-robotic-surgery-at-a-tertiary-childrens-hospital-100626674","NCT07438704","Outcomes of Pediatric Robotic Surgery at a Tertiary Children's Hospital","Outcomes of Pediatric Robotic Surgery at a Tertiary Children's Hospital: A Retrospective Cohort Study","ROB-PED","Inclusion Criteria:\n\n* Age \\\u003C 18 years at the time of surgery\n* Underwent robotic-assisted surgical procedure (digestive, urologic, gynecologic, or thoracic surgery)\n* Surgery performed between January 2025 and December 2025 at Meyer Children's Hospital IRCCS\n* Availability of essential clinical and perioperative data in the medical record\n\nExclusion Criteria:\n\n* Missing essential clinical or postoperative data required for analysis\n* Documented opposition to the use of clinical data for research purposes","0 Days",{"count":52,"type":21},100,"OBSERVATIONAL","This is a single-center retrospective observational cohort study evaluating surgical and clinical outcomes in pediatric patients undergoing robotic surgery at a tertiary children's hospital.\n\nAll consecutive patients younger than 18 years who underwent robotic-assisted procedures (digestive, urologic, gynecologic, or thoracic surgery) between January 2025 and December 2025 at Meyer Children's Hospital IRCCS will be included.\n\nThe primary objective is to describe postoperative complications within 30 days. Secondary objectives include conversion to open surgery, reintervention and readmission rates, length of hospital stay, postoperative pain, recovery parameters, and recurrence of the underlying disease within 12 months.\n\nData will be collected retrospectively from electronic medical records, operative registries, laboratory reports, and follow-up documentation up to 12 months after surgery.",[28],[28],"NOT_YET_RECRUITING","2026-02-27",{"date":60,"type":33},"2026-03-02",{"date":62,"type":21},"2026-03",{"date":64,"type":21},"2026-12",{"name":66,"class":40},"Meyer Children's Hospital IRCCS",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100551387","a-multicenter-randomized-controlled-umbrella-trial-for-minimally-invasive-neurosurgery-with-ai-assisted-robotic-guidance-for-hemorrhagic-stroke-100551387","NCT06459427","A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke","Robot-Assisted Minimally Invasive Surgery for Brainstem Hemorrhage","RAINBOW-BSH","Participants must meet all of the following inclusion criteria:\n\n1. Age ≥18 years at randomization；\n2. Diagnosed with brainstem hemorrhage via imaging (CT, CTA, etc.)；\n3. Hematoma volume ≥3 mL；\n4. Glasgow Coma Scale (GCS) score of 3-12；\n5. Available for surgery within 48 hours after onset；\n6. Modified Rankin Scale (mRS) score ≤ 1 prior to this hemorrhage；\n7. Informed consent obtained in accordance with national laws, regulations, and applicable ethics committee requirements.\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Hematoma involving other regions such as the supratentorial compartment, basal ganglia, thalamus, midbrain, or ventricles.\n2. Radiologically confirmed cerebral vascular abnormalities including ruptured aneurysms, arteriovenous malformations (AVMs), or Moyamoya disease; hemorrhagic transformation of ischemic infarcts; or recent (within 1 year) recurrence of intracerebral hemorrhage；\n3. Any irreversible coagulation disorder or known coagulopathy; platelet count \\\u003C100,000\u002FµL; INR \\>1.4; or use of anticoagulant medication within 7 days before the current hemorrhage；\n4. Current or probable pregnancy；\n5. Patients with concurrent severe illness likely to influence outcome assessment；\n6. Difficulty in follow-up or poor compliance due to any cause.",{"count":76,"type":21},142,[24],"The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are:\n\n* Establish a multi-center clinical database for brainstem hemorrhage.\n* Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits.\n* Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning.\n\nParticipants in the experimental group will:\n\n* Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture\n* Receive conservative non-surgical treatment.\n\nIf there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.",[80,28],"Brain Stem Hemorrhage","2026-02-10",{"date":83,"type":33},"2026-02-12",{"date":85,"type":21},"2026-04",{"date":87,"type":21},"2027-12",{"name":89,"class":40},"Yanbing Yu",3,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":114,"locationsCount":41},"100618529","site-of-tracheal-extubation-and-operating-room-efficiency-during-robot-assisted-surgery-100618529","NCT07332806","Site of Tracheal Extubation and Operating Room Efficiency During Robot-assisted Surgery","Impact of Site of Tracheal Extubation on Operating Room Efficiency During Robot-assisted Surgery: a Randomized Trial","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Scheduled to undergo elective robot-assisted laparoscopic surgery under general anesthesia;\n3. Expected tracheal extubation during daytime working hours (before 4:00 PM).\n\nExclusion Criteria:\n\n1. Refuse to participate in the study;\n2. Morbid obesity (body mass index ≥35 kg\u002Fm²);\n3. Preoperatively diagnosed obstructive sleep apnea, or patients with a STOP-Bang score ≥3 in combination with serum bicarbonate (HCO₃-) ≥28 mmol\u002FL;\n4. Patients at high risk of difficult airway (anticipated difficult intubation and\u002For extubation during preoperative assessment);\n5. Preexisting sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), or second-degree or higher atrioventricular block without pacemaker implantation; congenital heart disease with any type of arrhythmia; or other severe cardiovascular diseases with New York Heart Association (NYHA) functional class ≥III;\n6. Significant pulmonary function impairment (FEV₁\u002FFVC ratio \\\u003C 70%, and total lung capacity \\[TLC\\] and vital capacity \\[VC\\] \\\u003C 80% of predicted values);\n7. Severe hepatic dysfunction (Child-Pugh class C); severe renal dysfunction (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²); or American Society of Anesthesiologists (ASA) physical status classification ≥IV;\n8. Preoperative diagnoses of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n9. Inability to communicate due to coma, severe dementia, or language impairment;\n10. Planned postoperative admission to the intensive care unit;\n11. Any other conditions that are deemed for study participation.",{"count":99,"type":21},218,[24],"This study aims to evaluate the impact of different extubation strategy on the occupancy time of operating room (OR) and the incidence of adverse events and quality of recovery after robotic-assisted surgery. The investigators hypothesize that extubation in the post-anesthesia care unit (PACU) may reduce OR occupancy time without increasing adverse events or worsening quality of recovery early after robotic-assisted surgery. This strategy may enhance perioperative efficiency while maintaining clinical safety.",[28,103,104,105,106],"Airway Extubation","Operating Rooms","Anesthesia Recovery Period","Postoperative Complications",[28,103,104,105,106],"2026-01-13",{"date":110,"type":33},"2026-01-15",{"date":112,"type":33},"2026-01-12",{"date":85,"type":21},{"name":115,"class":40},"Peking University First Hospital",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":124,"minAge":17,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":90},"100610917","day-care-in-robotic-surgery-hysterectomy-investigate-quality-of-life-and-safety-with-same-day-discharge-after-robotic-hysterectomy-for-patients-with-benign-and-malignant-disease-a-multicenter-randomized-study-with-3-hospitals-in-stockholm-sweden-100610917","NCT07233811","Day Care in Robotic Surgery Hysterectomy. Investigate Quality of Life and Safety With Same Day Discharge After Robotic Hysterectomy for Patients With Benign and Malignant Disease. A Multicenter Randomized Study With 3 Hospitals in Stockholm Sweden.","DARSH - A Multicenter Randomized Controlled Trial: Day-care vs Overnight Stay in Robotic Assisted Hysterectomy in Patients With Bening Disease and Endometrial Cancer.","DARSH","Inclusion Criteria:\n\n* Patient that are planned to undergo total robotic hysterectomy with or without adnexal surgery at the three sites.\n* Both benign conditions and endometrial cancer.\n* All BMI groups and all uterus sizes.\n\nExclusion Criteria:\n\n* Age not over 75 years old,\n* No company at home first night after surgery\n* ASA class 3 that is not only because of high BMI.\n* Simultaneous prolapse surgery\u002Flymph node evacuation.\n* Severe endometriosis or patients with chronic pain conditions that have a special pain regimen after surgery.","FEMALE","75 Years",{"count":127,"type":21},300,[24],"Patients undergoing robotic assisted hysterectomy in three different hospitals in Stockholm will be randomized to day-care (going home the same day as the surgery) or admission (staying at least one night after surgery). The aim with this study is to investigate if patients in day-care recover as fast\u002Ffaster as the other group that stays in the hospital. Both patients with benign disease and malign disease (endometrial cancer) will be included in the study.\n\nPatients quality of life (QoL) will be measured before surgery and after surgery at day 3,7 and 30 with a questionnaire called Eq-5D-5L from Euroqol. The questionnaire is validated for postoperative QoL and widely used.\n\nComplications due to surgery within the 30 first days after surgery will also be recorded in the two groups to make sure it is safe for the patients to go home the same day as their surgery.",[131,132,28],"Hysterectomy","Same Day Discharge",[131,134,135,136],"Same day discharge","Robotic assisted Hysterectomy","Robotic suregery","2025-11-16",{"date":139,"type":33},"2025-11-18",{"date":141,"type":33},"2025-01-01",{"date":143,"type":21},"2028-01",{"name":145,"class":40},"Karolinska Institutet",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":41},"100579468","single-port-versus-multi-port-robotic-surgery-for-rectal-cancer-100579468","NCT06824688","Single-port Versus Multi-port Robotic Surgery for Rectal Cancer","Efficacy and Safety Assessment of Single-port Versus Multi-port Robotic Surgery for Rectal Cancer: a Phase 2a Non-randomized Controlled Study Based on the IDEAL Framework","Inclusion criteria comprised: (1) MRI-confirmed distal tumor margin \\\u003C15 cm from the anal verge, (2) biopsy-proven adenocarcinoma, (3) clinical stage I-III (AJCC 8th edition) with potential downstaging post-neoadjuvant therapy, (4) intent-to-treat with sphincter preservation and primary anastomosis, (5) documented informed consent, and (6) adult patients (≥18 years).",{"count":154,"type":21},40,[24],"Single-port versus multi-port robotic surgery for rectal cancer",[158,28],"Rectal Cancer Patients","2025-09-15",{"date":161,"type":33},"2025-09-19",{"date":163,"type":33},"2024-10-23",{"date":165,"type":21},"2025-12-31",{"name":167,"class":40},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":174,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100595208","comparison-of-short--and-long-term-outcomes-between-robotic-and-laparoscopic-hemicolectomy-of-right-colon-cancer--a-multicenter-propensity-score-matching-analysis-100595208","NCT07029464","Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis","Inclusion Criteria:\n\n* 1.Underwent radical right hemicolectomy by Da Vinci robotic or laparoscopic surgery 2.Postoperative pathology confirmed right colon adenocarcinoma (pT2-T4aNxM0; including cecal adenocarcinoma, ascending colon adenocarcinoma, hepatic flexure colon adenocarcinoma, and proximal transverse colon adenocarcinoma) 3.Complete clinical data and pathological results available\n\nExclusion Criteria:\n\n* 1.Received neoadjuvant therapy prior to surgery 2.History of other malignancies in the past 5 years (except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin) 3.Distant metastases (e.g., liver, lung) or extensive abdominal\u002Fpelvic metastases confirmed by contrast-enhanced CT, PET-CT, or intraoperative exploration 4.Comorbid neurological\u002Fpsychiatric disorders impairing ability to express informed consent 5.Poor systemic condition with contraindications to general anesthesia 6.Severe obesity (BMI \\>35 kg\u002Fm²) 7.Severe widespread abdominal adhesions precluding safe pneumoperitoneum establishment 8.Emergency surgery due to tumor perforation or obstruction 9.Refusal to provide informed consent",{"count":175,"type":21},4000,"This is a retrospective, multicenter cohort study to compare short- and long-term outcomes between robotic and laparoscopic hemicolectomy of right colon cancer.",[28,178,179,180],"Right Colon Tumors","Cancer","Laparoscopic Abdominal Surgery",[182,183],"right colon cancer","robotic surgery","2025-06-17",{"date":186,"type":33},"2025-06-19",{"date":188,"type":21},"2025-06",{"date":190,"type":21},"2027-05",{"name":192,"class":40},"The First Affiliated Hospital of Nanchang University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":203,"studyType":53,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100585200","sparobopan-project-spanish-registry-of-robotic-pancreatic-surgery-100585200","NCT06899269","SPAROBOPAN Project (Spanish Registry of Robotic Pancreatic Surgery)","Proyecto SPAROBOPAN (Registro Nacional De Cirugía Róbotica Pancreática)","SPAROBOPAN","Inclusion Criteria:\n\n* robotic pancreatic resections\n* Asa I-III\n* Signed informed consent\n\nExclusion Criteria:\n\n* Less than 18 years old.\n* ASA IV",{"count":202,"type":21},225,"3 Years","Pancreatic robotic surgery (PRS) has moved from an almost testimonial procedure to a moment of expansion that is not yet clearly defined. In the pioneering centres, the results achieved are superior to those of open surgery. At present, it is not known how many centres perform CRP, what type of operations they perform, what percentage of the total number of pancreatic operations CRP represents and what results are obtained. The aim of our project is to establish a national multicentre registry of robotic pancreatic surgery that will allow us to answer all these questions.\n\nMethodology: This is a one-year prospective multicentre registry involving all general and digestive surgery units in Spain that have a DaVinci robotic platform and wish to participate and perform robotic pancreatectomies.\n\nAll adult patients undergoing robotic pancreatectomy at participating Spanish centres who meet the inclusion criteria will be included. The registry will be open until 31 March 2026 to include post-operative morbidity and mortality at 90 days. The number of pancreatic surgeries performed in that centre during the same period will be counted to determine the percentage of robotic pancreatic surgery per centre. Intraoperative complications will be measured according to the Satava classification modified by Halls et al. Postoperative complications will be classified according to the Clavien-Dindo classification and the CCI (Comprehensive Complication Index). Pancreatic fistula, postoperative bleeding and delayed gastric emptying were classified according to the ISGPS classification and biliary fistula according to the ISGLS classification.",[28,206],"Pancreatic Diseases","2025-03-21",{"date":209,"type":33},"2025-03-27",{"date":211,"type":21},"2025-04-01",{"date":213,"type":21},"2029-06-30",{"name":215,"class":40},"Hospital General Universitario de Alicante",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":41},"100524167","ratme-vs-latme-in-middle-and-low-rectal-cancer-100524167","NCT06105203","RATME Vs LATME in Middle and Low Rectal Cancer","A Multicenter Randomized Clinical Trial to Assess the Advantages of Robotic Total Mesorectal Excision in Preserving External Sphincter in Patients with Middle and Low Rectal Cancer.","Inclusion Criteria:\n\n1. male patients diagnosed with rectal cancer by pathological biopsy;\n2. abdominal contrast-enhanced and chest computed tomography (CT) or positron emission tomography-computed tomography (PET-CT) revealed no distal metastasis;\n3. Preoperative rectal magnetic resistance (MR) evaluation showed that the tumor was located at or below the peritoneal reflux plane, and at least 1cm above the anal sphincter groove, and did not invade the external anal sphincter;\n4. Tumors located above the hiatus of levator ani muscle were evaluated by magnetic resonance imaging as cT1-3, cN0-1, M0, and MRF (-); The tumors located below the hiatus of levator ani muscle were evaluated by magnetic resonance imaging as cT1-2, cN0-1, M0, and MRF (-). After neoadjuvant treatment, the tumor above the hiatus of levator ani muscle is ycT3NxM0 or below; The tumor below the hiatus of levator ani muscle is ycT2NxM0;\n5. The patient underwent laparoscopic assisted TME surgery or robotic assisted TME surgery.\n\nExclusion Criteria:\n\n1. multiple primary cancers;\n2. history of open surgery;\n3. no preoperative MR evaluation and inadequate evaluation of tumor stage;\n4. Patients with rectal cancer who undergo endoscopic resection first and need subsequent transabdominal resection;\n5. Pregnant or patients with concomitant inflammatory bowel disease;\n6. Patients with preoperative complete bowel obstruction or requiring emergency surgery;\n7. Preoperative evaluation indicates that patient may require combined organ resection;\n8. Recently receiving treatment for other malignant tumors;\n9. Bordeaux type IV low rectal cancer;\n10. The preoperative pathological types are signet ring cell carcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, or poorly differentiated carcinoma.\n\nExit Criteria\n\n1. Refuse surgical treatment after randomization;\n2. Open surgery was performed for treatment after randomization;\n3. Patients request to withdraw from the study at any time during the entire study process after randomization",{"count":224,"type":21},1026,[24],"This is a multicenter, superior, randomized controlled trial designed to compare Robotic-assisted total mesorectal excision (RATME) and laparoscopic-assisted total mesorectal excision (LATME) for middle and low rectal cancer. The primary endpoint is the incidence of intersphincteric resection (ISR). The secondary outcomes are coloanal anastomosis (CAA), conversion to open, conversion to transanal TME (TaTME), incidence of abdominoperineal resection (APR), postoperative morbidity and mortality within 30 days after surgery, pathological outcomes, long-term survival outcomes, functional outcomes, and quality of life.",[228,229,28,230],"Total Mesorectal Excision","Rectal Neoplasms","Laparoscopy","2025-02-16",{"date":233,"type":33},"2025-02-19",{"date":235,"type":21},"2025-11-01",{"date":237,"type":21},"2031-01",{"name":239,"class":40},"The First Hospital of Jilin University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":255,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":41},"100571189","a-study-of-3d-visualization-techniques-to-improve-the-quality-and-safety-of-robot-assisted-nephron-sparing-surgery-for-complex-renal-tumors-100571189","NCT06717009","A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors.","A Prospective, Multicenter, Randomized Controlled Study of Three-dimensional Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors","Inclusion Criteria:\n\n1. The imaging diagnosis is single renal cell carcinoma, clinical stage is T1N0M0-T2N0M0, and the contralateral kidney function is good.\n2. Physical status and organ function allow robotic-assisted partial nephrectomy.\n3. Be able to adhere to the protocol during the study.\n4. The age ranges from 18 to 75 years, and there is no chronic kidney disease.\n5. KPS \\> 80; ECOG score: 0-1; There are no other serious concomitant diseases and the organ function is good.\n6. There are no medical contraindications seriously affecting anesthesia and surgery.\n7. The patient has no history of other malignant tumors in the past 5 years.\n8. There is no surgical history of epigastrium and the affected kidney.\n9. Estimated survival is more than 6 months, and there are no other severe diseases that reduce survival to less than 5 years.\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating, or who are of reproductive age and are not using effective contraception.\n2. Comorbid serious medical diseases or conditions, for example, clinically severe or active heart disease, severe uncontrolled medical illnesses and infections, severe uncontrolled digestive disorder, severe electrolyte disturbance, active disseminated intravascular coagulation, major organ failure such as decompensated cardiac, pulmonary, hepatic, or renal failure, symptomatic peripheral neuropathy. Can not tolerate robot-assisted laparoscopic partial nephrectomy\n3. Organ transplant recipients requiring immunosuppressive therapy.\n4. There is history of other malignancies within 5 years of trial initiation, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.\n5. Patients who have received biological therapy or other anticancer traditional Chinese medicine within 4 weeks.\n6. Patients with multiple or bilateral renal tumors or solitary renal tumors.\n7. Patient without complete clinical information.",{"count":248,"type":21},350,[24],"The goal of this clinical trial is to learn the evidence-based medical value of 3D visualization techniques to improve tumor control, preservation of renal function, and perioperative safety in robot-assisted nephron sparing surgery for complex renal tumors. The main question it aims to answer is:\n\nIs 3D visualization techniques more effective in improving robot-assisted nephron sparing surgery for complex renal tumors in terms of tumor control, renal function preservation, and perioperative safety.\n\nThe researchers will randomize participants into a 3D trial group and a conventional group for comparison.\n\nParticipants will:\n\nComplete Blood routine, liver and kidney function tests on the first and third day after operation.\n\nHave Renography at 3 and 12 months after the operation. Cooperate with follow-up visits.",[252,28,253,254],"Kidney Neoplasms \u002F Surgery","Imaging, Three-Dimensional \u002F Methods","Nephrectomy \u002F Methods",[256,257,258,259,230,260],"Three-dimensional visualization technique;","Three-dimensional reconstruction","Robotic surgery","Kidney neoplasms","Nephron sparing surgery","2024-11-29",{"date":263,"type":33},"2024-12-04",{"date":265,"type":21},"2025-01",{"date":267,"type":21},"2027-10",{"name":269,"class":40},"Tianjin Medical University Cancer Institute and Hospital",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":277,"targetDuration":203,"studyType":53,"phases":4,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":41},"100556654","a-randomized-controlled-trial-of-the-sagittal-alignment-difference-between-mako-robotic-tka-and-manual-tka-100556654","NCT06527911","A Randomized Controlled Trial of the Sagittal Alignment Difference Between Mako Robotic TKA and Manual TKA","A Randomized Controlled Trial of the Sagittal Alignment Difference Between Mako Robotic Total Knee Arthroplasty and Manual Total Knee Arthroplasty","Inclusion Criteria:\n\n1. The age ranged from 18 to 80 years old;\n2. OA patients who underwent Mako robot assisted TKA and manual TKA (Stryker Triathlon prosthesis) in the Department of joint surgery of the PLA General Hospital from September 2024 to September 2026;\n3. All patients were required to take full-length anteroposterior and lateral radiographs of lower limbs, anteroposterior and lateral radiographs of both knees, and lower limb sagittal EOS before and after surgery;\n4. Physical and mental health, able to participate in and cooperate with the test;\n5. Patients are willing to participate in the study and sign written informed consent.\n\nExclusion Criteria:\n\n1. People unable to conduct EOS inspection;\n2. Combined with knee meniscus injury, anterior cruciate ligament injury and other diseases that may affect the sagittal force line of the knee joint\n3. Combined with other diseases that may affect the study\n4. Patients refused to use their imaging data and knee score for this study.",{"count":52,"type":21},"As China transitions into an aging society, the proportion of the elderly population is escalating, with a corresponding rise in the number of patients with knee joint diseases. Total knee arthroplasty stands as an effective treatment for joint disorders, effectively reducing knee pain, restoring functionality, and enhancing quality of life. The objectives of total knee arthroplasty are to relieve pain, restore function, and ensure a long-lasting implant. In recent years, technological advancements have integrated robotic assistance into total knee arthroplasty (TKA), aiding surgeons in planning and executing more accurate surgical plans, significantly enhancing precision and post-operative outcomes. However, the Mako mechanical axis alignment demonstrated during the Mako robot-assisted TKA procedure does not correspond to the actual straightening of the lower limb, and discrepancies may exist in sagittal alignment between Mako-assisted and manual TKA procedures, necessitating adjustments by surgeons based on their experience. Consequently, there is an urgent need to develop a mathematical formula that quantifies these differences to guide intraoperative alignment. Additionally, the Mako-assisted TKA femoral prosthesis exhibits a head-lowering issue, and differences exist in the posterior slope angle of the tibial plateau compared to manual TKA, necessitating further comparative analysis to draw definitive conclusions. This study will be carried out at the People's Liberation Army General Hospital, with an anticipated enrollment of approximately 100 participants.",[280,281,282,283,28],"Arthroplasty","Replacement","Knee","Osteoarthritis","2024-07-25",{"date":286,"type":33},"2024-07-30",{"date":288,"type":21},"2024-09-01",{"date":290,"type":21},"2026-09-01",{"name":292,"class":40},"Chinese PLA General Hospital",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":301,"targetDuration":303,"studyType":53,"phases":4,"briefSummary":304,"conditions":305,"keywords":310,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":41},"100485399","registry-of-the-spanish-society-of-thoracic-surgery-100485399","NCT05600569","Registry of the Spanish Society of Thoracic Surgery","Registry of the Spanish Society of Thoracic Surgery (ReSECT)","ReSECT","The inclusion criteria will depend on the section of the registry to be considered.\n\n* Personal registry: patients undergoing any type of surgical intervention.\n* Registry of surgical processes by departments: patients undergoing an anatomical pulmonary resection as the first process to be implemented at the time ReSECT is to be established.\n\nExclusion Criteria:\n\n* Patients who could reject to participate in this study.",{"count":302,"type":21},30000,"5 Years","ReSECT is a project promoted by the Spanish Society of Thoracic Surgery with the aim not only to become an indefinite, dynamic and inclusive registry, but also to establish a common structural framework for the development of future multicentre projects in the field of thoracic surgery in Spain.\n\nThe goal of this nationwide prospective observational registry is:\n\n* To develop and validate forecasting tools based on powerful computational methods with the goal of assisting in decision-making and improving quality of care.\n* To evaluate the progressive implementation of certain surgical techniques that are on the rise, new technologies and future health programs.\n* To be aware of our results as specialty and professionals and to serve as a permanent benchmarking instrument in thoracic surgery.\n\nThe first part of ReSECT, based on a personal registry design, will contemplate any thoracic surgical procedure performed by thoracic surgeons and residents in thoracic surgery in our country. Additionally, the Spanish thoracic surgery departments that voluntarily accept to collectively participate will contribute to specific surgical processes focused on certain procedures with specific objectives to be progressively implemented.\n\nThe first and only surgical process implemented since the start of the ReSECT project will focus on patients to undergo anatomical lung resection with special interest in those cases whose reason for intervention was lung cancer.\n\nThe main questions to answer in case of that first surgical process include:\n\n* What is the performance of current predictive models for perioperative and oncological outcomes in our country?\n* How could we modify previous predictive models to improve their performance?\n* What is the implementation of current guideline recommendations in our country and across institutions?\n* What is the potential impact of deviations from current recommendations?\n* What is my performance compared to the rest of the thoracic surgical departments in my country in terms of perioperative and oncological outcomes?\n\nReSECT does not consider prespecified comparison groups of patients.",[306,307,28,308,309],"Pulmonary Surgical Procedures","Thoracic Surgery, Video-assisted","Thoracotomy","Lung Neoplasm",[311,312,313],"Pneumonectomy","Lobectomy","Segmentectomy","2023-10-18",{"date":316,"type":33},"2023-10-19",{"date":318,"type":33},"2023-01-01",{"date":320,"type":21},"2032-12-31",{"name":322,"class":40},"Sociedad Española de Cirugía Torácica"]